How I Treat How we treat higher-risk myelodysplastic syndromes

s. 2012;120(21):1696. 73. Itzykson R, Kosmider O, Cluzeau T, et al;Groupe Francophone des Myelodysplasies(GFM). Impact of TET2 mutations on responserate to azacitidine in myelodysplastic syndromesand low blast count acute myeloid leukemias.Leukemia. 2011;25(7):1147-1152. 74. Sekeres MA, List AF, Cuthbertson D, et al.Phase I combination trial of lenalidomide andazacitidine in patients with higher-riskmyelodysplastic syndromes. J Clin Oncol. 2010;28(13):2253-2258. 75. Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2study of the lenalidomide and azacitidinecombination in patients with higher-riskmyelodysplastic syndromes. Blood. 2012;120(25):4945-4951. 76. Cameron EE, Bachman KE, Myöhänen S,Herman JG, Baylin SB. Synergy ofdemethylation and histone deacetylase inhibitionin the re-expression of genes silenced in cancer.Nat Genet. 1999;21(1):103-107. 77. Gore SD, Baylin S, Sugar E, et al. CombinedDNA methyltransferase and histone deacetylaseinhibition in the treatment of myeloid neoplasms.Cancer Res. 2006;66(12):6361-6369. 78. Silverman LR, Verma A, Odchimar-Reissig R,et al. A phase I trial of the epigenetic modulatorsvorinostat, in combination with azacitidine (azaC)in patients with the myelodysplastic syndrome(MDS) and acute myeloid leukemia (AML):a study of the New York Cancer Consortium.ASH Annual Meeting Abstracts. 2008;112(11):3656. 79. Garcia-Manero G, Estey EH, Jabbour E, et al.Phase II study of 5-azacitidine and vorinostatin patients (pts) with newly diagnosedmyelodysplastic syndrome (MDS) or acutemyelogenous leukemia (AML) not eligible forclinical trials because poor performance orpresence of other comorbidities. ASH AnnualMeeting Abstracts. 2011;116(21):604. 80. Prebet T, Gore SD, Sun Z, et al. Prolongedadministration of azacitidine with or withoutentinostat increases rate of hematologicnormalization for myelodysplastic syndrome andacute myeloid leukemia with myelodysplasia-related changes: results of the US LeukemiaIntergroup Trial E1905. ASH Annual MeetingAbstracts. 2010;116(21):601. 81. Prébet T, Gore SD, Esterni B, et al. Outcome ofhigh-risk myelodysplastic syndrome afterazacitidine treatment failure. J Clin Oncol. 2011;29(24):3322-3327. 82. Jabbour E, Garcia-Manero G, Batty N, et al.Outcome of patients with myelodysplasticsyndrome after failure of decitabine therapy.Cancer. 2010;116(16):3830-3834. 83. Sekeres MA, Roboz GJ, Odenike O, et al.Preliminary results of fixed-dose oralclofarabine (CLO) in patients who have failedhypomethylating agents for the treatment ofmyelodysplastic syndromes (MDS). ASH AnnualMeeting Abstracts. 2010;116(21):1869. 84. Bello C, Yu D, Komrokji RS, et al. Outcomesafter induction chemotherapy in patients withacute myeloid leukemia arising frommyelodysplastic syndrome. Cancer. 2011;